ITOS Stock Overview
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
iTeos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.50 |
| 52 Week High | US$18.75 |
| 52 Week Low | US$8.20 |
| Beta | 1.4 |
| 11 Month Change | 11.25% |
| 3 Month Change | -2.02% |
| 1 Year Change | 48.94% |
| 33 Year Change | -35.85% |
| 5 Year Change | n/a |
| Change since IPO | -8.14% |
Recent News & Updates
Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?
Aug 11
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
Jul 09Recent updates
Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?
Aug 11iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
Jul 09iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 25iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Jan 10Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%
May 13Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding
Mar 21The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically
Aug 12iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04
Aug 10iTeos Therapeutics: Too Many Unknowns
Jul 27News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts
May 11Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Nov 25We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
Aug 15GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler
Jun 15We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?
Dec 16
iTeos Therapeutics EPS misses by $0.11
Nov 12Shareholder Returns
| ITOS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.6% | 3.5% | 3.1% |
| 1Y | 48.9% | 14.9% | 25.4% |
Return vs Industry: ITOS exceeded the US Biotechs industry which returned 15.7% over the past year.
Return vs Market: ITOS exceeded the US Market which returned 25.6% over the past year.
Price Volatility
| ITOS volatility | |
|---|---|
| ITOS Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ITOS has not had significant price volatility in the past 3 months.
Volatility Over Time: ITOS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 157 | Michel Detheux | www.iteostherapeutics.com |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company’s lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
iTeos Therapeutics, Inc. Fundamentals Summary
| ITOS fundamental statistics | |
|---|---|
| Market cap | US$580.33m |
| Earnings (TTM) | -US$108.13m |
| Revenue (TTM) | US$35.00m |
18.3x
P/S Ratio-5.9x
P/E RatioIs ITOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITOS income statement (TTM) | |
|---|---|
| Revenue | US$35.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$35.00m |
| Other Expenses | US$143.14m |
| Earnings | -US$108.13m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.96 |
| Gross Margin | 100.00% |
| Net Profit Margin | -308.96% |
| Debt/Equity Ratio | 0% |
How did ITOS perform over the long term?
See historical performance and comparison